|Dr. Desh Bandhu Gupta||Founder and Chairman||447.79M||N/A||N/A|
|Mrs. Vinita D. Gupta||Chief Exec. Officer and Exec. Director||190.17M||N/A||49|
|Dr. Kamal Kishore Sharm B.Eng (Chem) Ph.D.||Vice Chairman||133.02M||N/A||68|
|Mr. Nilesh D. Gupta||Managing Director and Exec. Director||75.91M||N/A||N/A|
|Mr. Ramesh Swaminathan||Chief Financial Officer and Exec. Director||20.83M||N/A||N/A|
Lupin Limited, a pharmaceutical company, develops, manufactures, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the areas of cardiology, central nervous system (CNS), diabetes, anti-asthma, gastro- intestinal, COPD, and gynecology; and APIs for use in therapeutic areas of cephalosporins, cardiovascular, and anti-TB. The company also develops drug delivery technologies; and biosimilars for various therapeutic indications, such as oncology, anti-inflammatory, anti-virals, rheumatoid arthritis, endocrinology, diabetes, ophthalmology, and womens health. In addition, it engages in the novel drug discovery and development programs for use in the treatment of CNS disorders, oncology, immunology, pain and inflammation, and metabolic disorders. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is based in Mumbai, India.
Lupin Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.